Q3 2024 Earnings Estimate for Amarin Co. plc (NASDAQ:AMRN) Issued By Zacks Research

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Analysts at Zacks Research increased their Q3 2024 earnings per share estimates for shares of Amarin in a report released on Wednesday, August 21st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.06). The consensus estimate for Amarin's current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Amarin's Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.15) EPS, Q1 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.11) EPS.

Several other research analysts have also commented on AMRN. StockNews.com lowered shares of Amarin from a "buy" rating to a "hold" rating in a report on Thursday, July 4th. Cantor Fitzgerald restated an "overweight" rating on shares of Amarin in a research report on Tuesday, June 18th.

Amarin Stock Up 1.4 %

AMRN stock traded up $0.01 during trading on Monday, hitting $0.64. 319,831 shares of the company's stock traded hands, compared to its average volume of 1,769,548. The stock has a market capitalization of $261.64 million, a price-to-earnings ratio of -5.31 and a beta of 1.95. Amarin has a 52 week low of $0.57 and a 52 week high of $1.37. The stock has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.85.

Insider Transactions at Amarin

In other Amarin news, CEO Aaron Berg purchased 160,000 shares of the stock in a transaction dated Friday, August 2nd. The shares were bought at an average cost of $0.64 per share, with a total value of $102,400.00. Following the completion of the acquisition, the chief executive officer now owns 805,380 shares of the company's stock, valued at $515,443.20. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.96% of the company's stock.

Institutional Trading of Amarin

A number of institutional investors have recently made changes to their positions in AMRN. Algert Global LLC bought a new stake in shares of Amarin in the 2nd quarter worth $34,000. Waterfront Wealth Inc. raised its position in Amarin by 63.7% in the second quarter. Waterfront Wealth Inc. now owns 860,613 shares of the biopharmaceutical company's stock worth $592,000 after acquiring an additional 334,969 shares in the last quarter. Longitude Cayman Ltd. lifted its holdings in Amarin by 1.5% in the 2nd quarter. Longitude Cayman Ltd. now owns 2,390,000 shares of the biopharmaceutical company's stock valued at $1,649,000 after acquiring an additional 35,000 shares during the last quarter. Prospect Financial Services LLC bought a new position in shares of Amarin during the 2nd quarter valued at about $41,000. Finally, Arkfeld Wealth Strategies L.L.C. acquired a new position in shares of Amarin in the 2nd quarter worth approximately $28,000. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.